Role of hepcidin-25 in chronic kidney disease: Anemia and beyond

Current Medicinal Chemistry

Volumn 24, Issue 14, 2017, Pages 1417-1452

  Ueda, Norishi ^a   Takasawa, Kazuya ^a  

^a Public Central Hospital of Matto Ishikawa   (Japan)

Author keywords

Anemia; Erythropoiesis; Ferritin; Hepcidin 25; Hypoxia; Inflammation; Iron; Kidney injury

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; FERRIC ION; GROWTH FACTOR; HEPCIDIN; HEPCIDIN 25; IRON; UNCLASSIFIED DRUG; VITAMIN D;

ANEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIESIS; HEMODIALYSIS; HOMEOSTASIS; HUMAN; HYPERPARATHYROIDISM; HYPOXIA; INFLAMMATION; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON OVERLOAD; METABOLIC REGULATION; MINERAL SUPPLEMENTATION; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN STRUCTURE; QUALITY OF LIFE; RADIOIMMUNOASSAY; REFERENCE VALUE; REVIEW; TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE; VITAMIN D DEFICIENCY; ANIMAL; METABOLISM;

ANEMIA; ANIMALS; HEPCIDINS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85025163427     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170316120538     Document Type: Review

References (353)

1. Geissler, C.; Singh, M. Iron, meat and health. Nutrients, 2011, 3(3), 283-316.
2. Krause, A.; Neitz, S.; Mägert, H.J.; Schulz, A.; Forssmann, W.G.; Schulz-Knappe, P.; Adermann, K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett., 2000, 480(2-3), 147-150.
3. Park, C.H.; Valore, E.V.; Waring, A.J.; Ganz, T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem., 2001, 276(11), 7806-7810.
4. Hentze, M.W.; Muckenthaler, M.U.; Galy, B.; Camaschella, C. Two to tango: regulation of Mammalian iron metabolism. Cell, 2010, 142(1), 24-38.
5. Kroot, J.J.; Tjalsma, H.; Fleming, R.E.; Swinkels, D.W. Hepcidin in human iron disorders: diagnostic implications. Clin. Chem., 2011, 57(12), 1650-1669.
6. Ganz, T. Systemic iron homeostasis. Physiol. Rev., 2013, 93(4), 1721-1741.
7. Meynard, D.; Babitt, J.L.; Lin, H.Y. The liver: conductor of systemic iron balance. Blood, 2014, 123(2), 168-176.
8. Rishi, G.; Wallace, D.F.; Subramaniam, V.N. Hepcidin: regulation of the master iron regulator. Biosci. Rep., 2015, 35(3), e00192.
9. Schmidt, P.J. Regulation of iron metabolism by hepcidin under conditions of inflammation. J. Biol. Chem., 2015, 290(31), 18975-18983.
10. Babitt, J.L.; Lin, H.Y. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am. J. Kidney Dis., 2010, 55(4), 726-741.
11. Nakanishi, T.; Kuragano, T.; Kaibe, S.; Nagasawa, Y.; Hasuike, Y. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin. Exp. Nephrol., 2012, 16(6), 819-826.
12. Canavesi, E.; Alfieri, C.; Pelusi, S.; Valenti, L. Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World. J. Nephrol., 2012, 1(6), 166-176.
13. Zumbrennen-Bullough, K.; Babitt, J.L. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol. Dial. Transplant., 2014, 29(2), 263-273.
14. Atkinson, M.A.; White, C.T. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pedi-atr. Nephrol., 2012, 27(1), 33-40.
15. Chaparro, C.M. Setting the stage for child health and development: prevention of iron deficiency in early infancy. J. Nutr., 2008, 138(12), 2529-2533.
16. Andrews, N.C. Disorders of iron metabolism. N. Engl. J. Med., 1999, 341(26), 1986-1995.
17. Gupta, P.M.; Perrine, C.G.; Mei, Z.; Scanlon, K.S. Iron, anemia, and iron deficiency anemia among young children in the United States. Nutrients, 2016, 8(6), E330.
18. Fomon, S.J.; Nelson, S.E.; Serfass, R.E.; Ziegler, E.E. Absorption and loss of iron in toddlers are highly correlated. J. Nutr., 2005, 135(4), 771-777.
19. Lynch, M.F.; Griffin, I.J.; Hawthorne, K.M.; Chen, Z.; Hamzo, M.G.; Abrams, S.A. Iron absorption is more closely related to iron status than to daily iron intake in 12-to 48-mo-old children. J. Nutr., 2007, 137(1), 88-92.
20. Butte, N.F.; Fox, M.K.; Briefel, R.R.; Siega-Riz, A.M.; Dwyer, J.T.; Deming, D.M.; Reidy, K.C. Nutrient intakes of US infants, toddlers, and preschoolers meet or exceed dietary reference intakes. J. Am. Diet. Assoc., 2010, 110(12)(Suppl.), S27-S37.
21. Clénin, G.; Cordes, M.; Huber, A.; Schumacher, Y.O.; Noack, P.; Scales, J.; Kriemler, S. Iron deficiency in sports-definition, influence on performance and therapy. Swiss Med. Wkly., 2015, 145, w14196.
22. Peters, H.P.; Laarakkers, C.M.; Pickkers, P.; Masereeuw, R.; Boerman, O.C.; Eek, A.; Cornelissen, E.A.; Swinkels, D.W.; Wetzels, J.F. Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrol., 2013, 14, 70.
23. Zaritsky, J.; Young, B.; Wang, H.J.; Westerman, M.; Ol-bina, G.; Nemeth, E.; Ganz, T.; Rivera, S.; Nissenson, A.R.; Salusky, I.B. Hepcidina potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2009, 4(6), 1051-1056.
24. Atkinson, M.A.; Kim, J.Y.; Roy, C.N.; Warady, B.A.; White, C.T.; Furth, S.L. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. Pediatr. Nephrol., 2015, 30(4), 635-643.
25. Troutt, J.S.; Butterfield, A.M.; Konrad, R.J. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J. Clin. Lab. Anal., 2013, 27(6), 504-510.
26. Kulaksiz, H.; Theilig, F.; Bachmann, S.; Gehrke, S.G.; Rost, D.; Janetzko, A.; Cetin, Y.; Stremmel, W. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J. Endocrinol., 2005, 184(2), 361-370.
27. Itkonen, O.; Stenman, U.H.; Parkkinen, J.; Soliymani, R.; Baumann, M.; Hämäläinen, E. Binding of hepcidin to plasma proteins. Clin. Chem., 2012, 58(7), 1158-1160.
28. Huang, M.L.; Austin, C.J.; Sari, M.A.; Rahmanto, Y.S.; Ponka, P.; Vyoral, D.; Richardson, D.R. Hepcidin bound to α2-macroglobulin reduces ferroportin-1 expression and enhances its activity at reducing serum iron levels. J. Biol. Chem., 2013, 288(35), 25450-25465.
29. De Domenico, I.; Ward, D.M.; di Patti, M.C.; Jeong, S.Y.; David, S.; Musci, G.; Kaplan, J. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J., 2007, 26(12), 2823-2831.
30. DAlessio, F.; Hentze, M.W.; Muckenthaler, M.U. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regula-tion. J. Hepatol., 2012, 57(5), 1052-1060.
31. Core, A.B.; Canali, S.; Babitt, J.L. Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeosta-sis. Front. Pharmacol., 2014, 5, 104.
32. Collins, J.F.; Wessling-Resnick, M.; Knutson, M.D. Hep-cidin regulation of iron transport. J. Nutr., 2008, 138(11), 2284-2288.
33. Thompson, J.W.; Bruick, R.K. Protein degradation and iron homeostasis. Biochim. Biophys. Acta., 2012, 1823(9), 1484-1490.
34. Rausa, M.; Pagani, A.; Nai, A.; Campanella, A.; Gilberti, M.E.; Apostoli, P.; Camaschella, C.; Silvestri, L. Bmp6 expression in murine liver non parenchymal cells: a mechanism to control their high iron exporter activity and protect hepatocytes from iron overload? PLoS One, 2015, 10(4), e0122696.
35. Zhao, N.; Zhang, A.S.; Enns, C.A. Iron regulation by hep-cidin. J. Clin. Invest., 2013, 123(6), 2337-2343.
36. Parrow, N.L.; Fleming, R.E. Bone morphogenetic proteins as regulators of iron metabolism. Annu. Rev. Nutr., 2014, 34, 77-94.
37. Andriopoulos, B., Jr; Corradini, E.; Xia, Y.; Faasse, S.A.; Chen, S.; Grgurevic, L.; Knutson, M.D.; Pietrangelo, A.; Vukicevic, S.; Lin, H.Y.; Babitt, J.L. BMP6 is a key en-dogenous regulator of hepcidin expression and iron metabolism. Nat. Genet., 2009, 41(4), 482-487.
38. Zhang, A.S.; Anderson, S.A.; Meyers, K.R.; Hernandez, C.; Eisenstein, R.S.; Enns, C.A. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J. Biol. Chem., 2007, 282(17), 12547-12556.
39. Zhao, N.; Maxson, J.E.; Zhang, R.H.; Wahedi, M.; Enns, C.A.; Zhang, A.S. Neogenin facilitates the induction of hepcidin expression by hemojuvelin in the liver. J. Biol. Chem., 2016, 291(23), 12322-12335.
40. Enns, C.A.; Ahmed, R.; Zhang, A.S. Neogenin interacts with matriptase-2 to facilitate hemojuvelin cleavage. J. Biol. Chem., 2012, 287(42), 35104-35117.
41. Maxson, J.E.; Chen, J.; Enns, C.A.; Zhang, A.S. Matriptase-2-and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin ex-pression. J. Biol. Chem., 2010, 285(50), 39021-39028.
42. Zhao, N.; Nizzi, C.P.; Anderson, S.A.; Wang, J.; Ueno, A.; Tsukamoto, H.; Eisenstein, R.S.; Enns, C.A.; Zhang, A.S. Low intracellular iron increases the stability of matriptase-2. J. Biol. Chem., 2015, 290(7), 4432-4446.
43. Meynard, D.; Vaja, V.; Sun, C.C.; Corradini, E.; Chen, S.; López-Otín, C.; Grgurevic, L.; Hong, C.C.; Stirnberg, M.; Gütschow, M.; Vukicevic, S.; Babitt, J.L.; Lin, H.Y. Regulation of TMPRSS6 by BMP6 and iron in human cells and mice. Blood, 2011, 118(3), 747-756.
44. Maurer, E.; Gütschow, M.; Stirnberg, M. Matriptase-2 (TMPRSS6) is directly up-regulated by hypoxia inducible factor-1: identification of a hypoxia-responsive element in the TMPRSS6 promoter region. Biol. Chem., 2012, 393(6), 535-540.
45. Schäfer, W.; Stroh, A.; Berghöfer, S.; Seiler, J.; Vey, M.; Kruse, M.L.; Kern, H.F.; Klenk, H.D.; Garten, W. Two independent targeting signals in the cytoplasmic domain de-termine trans-Golgi network localization and endosomal trafficking of the proprotein convertase furin. EMBO J., 1995, 14(11), 2424-2435.
46. Silvestri, L.; Pagani, A.; Camaschella, C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood, 2008, 111(2), 924-931.
47. Lin, L.; Nemeth, E.; Goodnough, J.B.; Thapa, D.R.; Gaba-yan, V.; Ganz, T. Soluble hemojuvelin is released by pro-protein convertase-mediated cleavage at a conserved poly-basic RNRR site. Blood Cells Mol. Dis., 2008, 40(1), 122-131.
48. Poli, M.; Luscieti, S.; Gandini, V.; Maccarinelli, F.; Finazzi, D.; Silvestri, L.; Roetto, A.; Arosio, P. Transferrin receptor 2 and HFE regulate furin expression via mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/Erk) signaling. Implications for transferrin-dependent hepcidin regulation. Haematologica, 2010, 95(11), 1832-1840.
49. Pinto, J.P.; Ribeiro, S.; Pontes, H.; Thowfeequ, S.; Tosh, D.; Carvalho, F.; Porto, G. Erythropoietin mediates hep-cidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood, 2008, 111(12), 5727-5733.
50. Liu, Q.; Davidoff, O.; Niss, K.; Haase, V.H. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J. Clin. Invest., 2012, 122(12), 4635-4644.
51. Tanno, T.; Porayette, P.; Sripichai, O.; Noh, S.J.; Byrnes, C.; Bhupatiraju, A.; Lee, Y.T.; Goodnough, J.B.; Harandi, O.; Ganz, T.; Paulson, R.F.; Miller, J.L. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood, 2009, 114(1), 181-186.
52. Robach, P.; Recalcati, S.; Girelli, D.; Gelfi, C.; Aachmann-Andersen, N.J.; Thomsen, J.J.; Norgaard, A.M.; Alberghini, A.; Campostrini, N.; Castagna, A.; Viganò, A.; Santam-brogio, P.; Kempf, T.; Wollert, K.C.; Moutereau, S.; Lundby, C.; Cairo, G. Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood, 2009, 113(26), 6707-6715.
53. Camaschella, C.; Pagani, A.; Nai, A.; Silvestri, L. The mutual control of iron and erythropoiesis. Int. J. Lab. Hema-tol., 2016, 38(Suppl. 1), 20-26.
54. Lee, P.; Peng, H.; Gelbart, T.; Wang, L.; Beutler, E. Regulation of hepcidin transcription by interleukin-1 and inter-leukin-6. Proc. Natl. Acad. Sci. USA, 2005, 102(6), 1906-1910.
55. Mayeur, C.; Lohmeyer, L.K.; Leyton, P.; Kao, S.M.; Pap-pas, A.E.; Kolodziej, S.A.; Spagnolli, E.; Yu, B.; Galdos, R.L.; Yu, P.B.; Peterson, R.T.; Bloch, D.B.; Bloch, K.D.; Steinbicker, A.U. The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by in-terleukin-6. Blood, 2014, 123(14), 2261-2268.
56. Pagani, A.; Nai, A.; Corna, G.; Bosurgi, L.; Rovere-Querini, P.; Camaschella, C.; Silvestri, L. Low hepcidin accounts for the proinflammatory status associated with iron deficiency. Blood, 2011, 118(3), 736-746.
57. Wu, X.; Yung, L.M.; Cheng, W.H.; Yu, P.B.; Babitt, J.L.; Lin, H.Y.; Xia, Y. Hepcidin regulation by BMP signaling in macrophages is lipopolysaccharide dependent. PLoS One, 2012, 7(9), e44622.
58. Weidenbusch, M.; Rodler, S.; Anders, H.J. Interleukin-22 in kidney injury and regeneration. Am. J. Physiol. Renal Physiol., 2015, 308(10), F1041-F1046.
59. Smith, C.L.; Arvedson, T.L.; Cooke, K.S.; Dickmann, L.J.; Forte, C.; Li, H.; Merriam, K.L.; Perry, V.K.; Tran, L.; Rottman, J.B.; Maxwell, J.R. IL-22 regulates iron availability in vivo through the induction of hepcidin. J. Immunol., 2013, 191(4), 1845-1855.
60. Armitage, A.E.; Eddowes, L.A.; Gileadi, U.; Cole, S.; Spottiswoode, N.; Selvakumar, T.A.; Ho, L.P.; Townsend, A.R.; Drakesmith, H. Hepcidin regulation by innate immune and infectious stimuli. Blood, 2011, 118(15), 4129-4139.
61. Vecchi, C.; Montosi, G.; Zhang, K.; Lamberti, I.; Duncan, S.A.; Kaufman, R.J.; Pietrangelo, A. ER stress controls iron metabolism through induction of hepcidin. Science, 2009, 325(5942), 877-880.
62. Shin, D.Y.; Chung, J.; Joe, Y.; Pae, H.O.; Chang, K.C.; Cho, G.J.; Ryter, S.W.; Chung, H.T. Pretreatment with CO-releasing molecules suppresses hepcidin expression during inflammation and endoplasmic reticulum stress through inhibition of the STAT3 and CREBH pathways. Blood, 2012, 119(11), 2523-2532.
63. Meynard, D.; Sun, C.C.; Wu, Q.; Chen, W.; Chen, S.; Nelson, C.N.; Waters, M.J.; Babitt, J.L.; Lin, H.Y. Inflammation regulates TMPRSS6 expression via STAT5. PLoS One, 2013, 8(12), e82127.
64. Qian, J.; Chen, S.; Huang, Y.; Shi, X.; Liu, C. PGC-1α regulates hepatic hepcidin expression and iron homeostasis in response to inflammation. Mol. Endocrinol., 2013, 27(4), 683-692.
65. Haase, V.H. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev., 2013, 27(1), 41-53.
66. Hintze, K.J.; McClung, J.P. Hepcidin: A critical regulator of iron metabolism during hypoxia. Adv. Hematol., 2011 2011, 510304.
67. Anderson, E.R.; Taylor, M.; Xue, X.; Martin, A.; Moons, D.S.; Omary, M.B.; Shah, Y.M. The hypoxia-inducible fac-tor-C/EBPα axis controls ethanol-mediated hepcidin repression. Mol. Cell. Biol., 2012, 32(19), 4068-4077.
68. Mastrogiannaki, M.; Matak, P.; Mathieu, J.R.; Delga, S.; Mayeux, P.; Vaulont, S.; Peyssonnaux, C. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica, 2012, 97(6), 827-834.
69. Lakhal, S.; Schödel, J.; Townsend, A.R.; Pugh, C.W.; Rat-cliffe, P.J.; Mole, D.R. Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis. J. Biol. Chem., 2011, 286(6), 4090-4097.
70. Sonnweber, T.; Nachbaur, D.; Schroll, A.; Nairz, M.; Seif-ert, M.; Demetz, E.; Haschka, D.; Mitterstiller, A.M.; Kleinsasser, A.; Burtscher, M.; Trübsbach, S.; Murphy, A.T.; Wroblewski, V.; Witcher, D.R.; Mleczko-Sanecka, K.; Vecchi, C.; Muckenthaler, M.U.; Pietrangelo, A.; Theurl, I.; Weiss, G. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut, 2014, 63(12), 1951-1959.
71. Choi, S.O.; Cho, Y.S.; Kim, H.L.; Park, J.W. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem. Biophys. Res. Com-mun., 2007, 356(1), 312-317.
72. Harrison-Findik, D.D.; Lu, S. The effect of alcohol and hydrogen peroxide on liver hepcidin gene expression in mice lacking antioxidant enzymes, glutathione peroxidase-1 or catalase. Biomolecules, 2015, 5(2), 793-807.
73. Millonig, G.; Ganzleben, I.; Peccerella, T.; Casanovas, G.; Brodziak-Jarosz, L.; Breitkopf-Heinlein, K.; Dick, T.P.; Seitz, H.K.; Muckenthaler, M.U.; Mueller, S. Sustained submicromolar H2O2 levels induce hepcidin via signal transducer and activator of transcription 3 (STAT3). J. Biol. Chem., 2012, 287(44), 37472-37482.
74. Miura, K.; Taura, K.; Kodama, Y.; Schnabl, B.; Brenner, D.A. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology, 2008, 48(5), 1420-1429.
75. Nishina, S.; Hino, K.; Korenaga, M.; Vecchi, C.; Pie-trangelo, A.; Mizukami, Y.; Furutani, T.; Sakai, A.; Okuda, M.; Hidaka, I.; Okita, K.; Sakaida, I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology, 2008, 134(1), 226-238.
76. Chen, S.; Feng, T.; Vujic Spasic, M.; Altamura, S.; Breit-kopf-Heinlein, K.; Altenöder, J.; Weiss, T.S.; Dooley, S.; Muckenthaler, M.U. Transforming growth factor β1 (TGF-β1) activates hepcidin mRNA expression in hepatocytes. J. Biol. Chem., 2016, 291(25), 13160-13174.
77. Goodnough, J.B.; Ramos, E.; Nemeth, E.; Ganz, T. Inhibition of hepcidin transcription by growth factors. Hepatol-ogy, 2012, 56(1), 291-299.
78. Ueda, N. Ceramide-induced apoptosis in renal tubular cells: a role of mitochondria and sphingosine-1-phoshate. Int. J. Mol. Sci., 2015, 16(3), 5076-5124.
79. Macdougall, I.C.; Malyszko, J.; Hider, R.C.; Bansal, S.S. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2010, 5(9), 1681-1689.
80. Busbridge, M.; Griffiths, C.; Ashby, D.; Gale, D.; Jayantha, A.; Sanwaiya, A.; Chapman, R.S. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br. J. Biomed. Sci., 2009, 66(3), 150-157.
81. Ganz, T.; Olbina, G.; Girelli, D.; Nemeth, E.; Westerman, M. Immunoassay for human serum hepcidin. Blood, 2008, 112(10), 4292-4297.
82. Uijterschout, L.; Swinkels, D.W.; Domellöf, M.; Lager-qvist, C.; Hudig, C.; Tjalsma, H.; Vos, R.; van Goudoever, J.B.; Brus, F. Serum hepcidin measured by immunochemi-cal and mass-spectrometric methods and their correlation with iron status indicators in healthy children aged 0.53 y. Pediatr. Res., 2014, 76(4), 409-414.
83. Butterfield, A.M.; Luan, P.; Witcher, D.R.; Manetta, J.; Murphy, A.T.; Wroblewski, V.J.; Konrad, R.J. A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin. Chem., 2010, 56(11), 1725-1732.
84. Tomosugi, N.; Kawabata, H.; Wakatabe, R.; Higuchi, M.; Yamaya, H.; Umehara, H.; Ishikawa, I. Detection of serum hepcidin in renal failure and inflammation by using Prote-inChip System. Blood, 2006, 108(4), 1381-1387.
85. Murphy, A.T.; Witcher, D.R.; Luan, P.; Wroblewski, V.J. Quantitation of hepcidin from human and mouse serum us-ing liquid chromatography tandem mass spectrometry. Blood, 2007, 110(3), 1048-1054.
86. Aeberli, I.; Hurrell, R.F.; Zimmermann, M.B. Overweight children have higher circulating hepcidin concentrations and lower iron status but have dietary iron intakes and bioavailability comparable with normal weight children. Int. J. Obes., 2009, 33(10), 1111-1117.
87. Anderson, D.S.; Kirchner, M.; Kellogg, M.; Kalish, L.A.; Jeong, J.Y.; Vanasse, G.; Berliner, N.; Fleming, M.D.; Steen, H. Design and validation of a high-throughput matrix-assisted laser desorption ionization time-of-flight mass spectrometry method for quantification of hepcidin in human plasma. Anal. Chem., 2011, 83(21), 8357-8362.
88. Young, M.F.; Griffin, I.; Pressman, E.; McIntyre, A.W.; Cooper, E.; McNanley, T.; Harris, Z.L.; Westerman, M.; OBrien, K.O. Maternal hepcidin is associated with placental transfer of iron derived from dietary heme and nonheme sources. J. Nutr., 2012, 142(1), 33-39.
89. Cangemi, G.; Pistorio, A.; Miano, M.; Gattorno, M.; Ac-quila, M.; Bicocchi, M.P.; Gastaldi, R.; Riccardi, F.; Gatti, C.; Fioredda, F.; Calvillo, M.; Melioli, G.; Martini, A.; Dufour, C. Diagnostic potential of hepcidin testing in pediatrics. Eur. J. Haematol., 2013, 90(4), 323-330.
90. Lorenz, L.; Herbst, J.; Engel, C.; Peter, A.; Abele, H.; Poets, C.F.; Westerman, M.; Franz, A.R. Gestational age-specific reference ranges of hepcidin in cord blood. Neona-tology, 2014, 106(2), 133-139.
91. Mupfudze, T.G.; Stoltzfus, R.J.; Rukobo, S.; Moulton, L.H.; Humphrey, J.H.; Prendergast, A.J. Hepcidin decreases over the first year of life in healthy African infants. Br. J. Haematol., 2014, 164(1), 150-153.
92. Sdogou, T.; Tsentidis, C.; Gourgiotis, D.; Marmarinos, A.; Gkourogianni, A.; Papassotiriou, I.; Anastasiou, T.; Kos-siva, L. Immunoassay-based serum hepcidin reference range measurements in healthy children: differences among age groups. J. Clin. Lab. Anal., 2015, 29(1), 10-14.
93. Malyszko, J.; Malyszko, J.S.; Pawlak, K.; Mysliwiec, M. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am. J. Hematol., 2006, 81(11), 832-837.
94. Grebenchtchikov, N.; Geurts-Moespot, A.J.; Kroot, J.J.; den Heijer, M.; Tjalsma, H.; Swinkels, D.W.; Sweep, F.G. High-sensitive radioimmunoassay for human serum hep-cidin. Br. J. Haematol., 2009, 146(3), 317-325.
95. Galesloot, T.E.; Vermeulen, S.H.; Geurts-Moespot, A.J.; Klaver, S.M.; Kroot, J.J.; van Tienoven, D.; Wetzels, J.F.; Kiemeney, L.A.; Sweep, F.C.; den Heijer, M.; Swinkels, D.W. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood, 2011, 117(25), e218-e225.
96. van der Weerd, N.C.; Grooteman, M.P.; Bots, M.L.; van den Dorpel, M.A.; den Hoedt, C.H.; Mazairac, A.H.; Nubé, M.J.; Penne, E.L.; Gaillard, C.A.; Wetzels, J.F.; Wieger-inck, E.T.; Swinkels, D.W.; Blankestijn, P.J.; Ter Wee, P.M. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One, 2012, 7(7), e39783.
97. Dale, J.C.; Burritt, M.F.; Zinsmeister, A.R. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. Am. J. Clin. Pathol., 2002, 117(5), 802-808.
98. Ford, B.A.; Coyne, D.W.; Eby, C.S.; Scott, M.G. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int., 2009, 75(1), 104-110.
99. Ford, B.A.; Eby, C.S.; Scott, M.G.; Coyne, D.W. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int., 2010, 78(8), 769-773.
100. Peters, H.P.; Rumjon, A.; Bansal, S.S.; Laarakkers, C.M.; van den Brand, J.A.; Sarafidis, P.; Musto, R.; Malyszko, J.; Swinkels, D.W.; Wetzels, J.F.; Macdougall, I.C. Intra-individual variability of serum hepcidin-25 in haemodialy-sis patients using mass spectrometry and ELISA. Nephrol. Dial. Transplant., 2012, 27(10), 3923-3929.
101. Zaritsky, J.; Young, B.; Gales, B.; Wang, H.J.; Rastogi, A.; Westerman, M.; Nemeth, E.; Ganz, T.; Salusky, I.B. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin. J. Am. Soc. Nephrol., 2010, 5(6), 1010-1014.
102. Schulze, K.J.; Christian, P.; Wu, L.S.; Arguello, M.; Cui, H.; Nanayakkara-Bind, A.; Stewart, C.P.; Khatry, S.K.; LeClerq, S.; West, K.P., Jr. Micronutrient deficiencies are common in 6-to 8-year-old children of rural Nepal, with prevalence estimates modestly affected by inflammation. J. Nutr., 2014, 144(6), 979-987.
103. Koshy, S.M.; Geary, D.F. Anemia in children with chronic kidney disease. Pediatr. Nephrol., 2008, 23(2), 209-219.
104. Casimiro de Almeida, J.; Lou-Meda, R.; Olbert, M.; Seifert, M.; Weiss, G.; Wiegerinck, E.T.; Swinkels, D.W.; Solomons, N.W.; Schümann, K. The growth attainment, hema-tological, iron status and inflammatory profile of guatemalan juvenile end-stage renal disease patients. PLoS One, 2015, 10(10), e0140062.
105. Chand, S.; Ward, D.G.; Ng, Z.Y.; Hodson, J.; Kirby, H.; Steele, P.; Rooplal, I.; Bantugon, F.; Iqbal, T.; Tselepis, C.; Drayson, M.T.; Whitelegg, A.; Chowrimootoo, M.; Borrows, R. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J. Nephrol., 2015, 28(1), 81-88.
106. Wagner, M.; Ashby, D.R.; Kurtz, C.; Alam, A.; Busbridge, M.; Raff, U.; Zimmermann, J.; Heuschmann, P.U.; Wanner, C.; Schramm, L. Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease. PLoS One, 2015, 10(4), e0123072.
107. Mercadal, L.; Metzger, M.; Casadevall, N.; Haymann, J.P.; Karras, A.; Boffa, J.J.; Flamant, M.; Vrtovsnik, F.; Stengel, B.; Froissart, M. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2012, 7(1), 35-42.
108. Nangaku, M.; Mimura, I.; Yamaguchi, J.; Higashijima, Y.; Wada, T.; Tanaka, T. Role of uremic toxins in erythropoie-sis-stimulating agent resistance in chronic kidney disease and dialysis patients. J. Ren. Nutr., 2015, 25(2), 160-163.
109. Warady, B.A.; Neu, A.M.; Schaefer, F. Optimal care of the infant, child, and adolescent on dialysis: 2014 update. Am. J. Kidney Dis., 2014, 64(1), 128-142.
110. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl., 2012, 2, 279-335.
111. Tsubakihara, Y.; Nishi, S.; Akiba, T.; Hirakata, H.; Iseki, K.; Kubota, M.; Kuriyama, S.; Komatsu, Y.; Suzuki, M.; Nakai, S.; Hattori, M.; Babazono, T.; Hiramatsu, M.; Ya-mamoto, H.; Bessho, M.; Akizawa, T. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther. Apher. Dial., 2010, 14(3), 240-275.
112. Camaschella, C. Iron-deficiency anemia. N. Engl. J. Med., 2015, 372(19), 1832-1843.
113. Bazeley, J.; Bieber, B.; Li, Y.; Morgenstern, H.; de Sequera, P.; Combe, C.; Yamamoto, H.; Gallagher, M.; Port, F.K.; Robinson, B.M. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin. J. Am. Soc. Nephrol., 2011, 6(10), 2452-2461.
114. Ryu, S.R.; Park, S.K.; Jung, J.Y.; Kim, Y.H.; Oh, Y.K.; Yoo, T.H.; Sung, S. The prevalence and management of anemia in chronic kidney disease patients: Result from the Korean cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD). J. Korean Med. Sci., 2017, 32(2), 249-256.
115. Minutolo, R.; Locatelli, F.; Gallieni, M.; Bonofiglio, R.; Fuiano, G.; Oldrizzi, L.; Conte, G.; De Nicola, L.; Man-gione, F.; Esposito, P.; Dal Canton, A. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol. Dial. Transplant., 2013, 28(12), 3035-3045.
116. Portolés, J.; Gorriz, J.L.; Rubio, E.; de Alvaro, F.; García, F.; Alvarez-Chivas, V.; Aranda, P.; Martinez-Castelao, A. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol., 2013, 14, 2.
117. Hörl, W.H.; Macdougall, I.C.; Rossert, J.; Rutkowski, B.; Wauters, J.P.; Valderrábano, F. Predialysis survey on anemia management: patient referral. Am. J. Kidney Dis., 2003, 41(1), 49-61.
118. Carlini, R.; Obrador, G.; Campistrús, N.; Andrade, L.; Chif-flet, L.; Bregman, R.; Locatelli, A.; Correa-Rotter, R.; Pob-lete, H. The first report of The Latin American Society of Nephrology and Hypertension (SLANH) Anemia Committee in chronic hemodialysis patients. Nefrologia, 2014, 34(1), 96-104.
119. Stauffer, M.E.; Fan, T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One, 2014, 9(1), e84943.
120. Wong, H.; Mylrea, K.; Feber, J.; Drukker, A.; Filler, G. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int., 2006, 70(3), 585-590.
121. Shaheen, F.A.; Souqiyyeh, M.Z.; Al-Attar, B.A.; Karkar, A.; Al Jazairi, A.M.; Badawi, L.S.; Ballut, O.M.; Hakami, A.H.; Naguib, M.; Al-Homrany, M.A.; Barhamein, M.Y.; Ahmed, A.M.; Khardaji, M.M.; Said, S.A. Prevalence of anemia in predialysis chronic kidney disease patients. Saudi J. Kidney Dis. Transpl., 2011, 22(3), 456-463.
122. Post, J.B.; Wilkes, B.M.; Michelis, M.F. Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin. Int. Urol. Nephrol., 2006, 38(3-4), 719-723.
123. Mercadal, L.; Metzger, M.; Haymann, J.P.; Thervet, E.; Boffa, J.J.; Flamant, M.; Vrtovsnik, F.; Gauci, C.; Froissart, M.; Stengel, B. A 3-marker index improves the identification of iron disorders in CKD anaemia. PLoS One, 2014, 9(2), e84144.
124. Małyszko, J.; Koc-Zórawska, E.; Levin-Iaina, N.; Małyszko, J.; Kozminski, P.; Kobus, G.; Mysliwiec, M. New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Pol. Arch. Med. Wewn., 2012, 122(11), 537-542.
125. Haupt, L.; Weyers, R. Determination of functional iron deficiency status in haemodialysis patients in central South Africa. Int. J. Lab. Hematol., 2016, 38(4), 352-359.
126. Staples, A.O.; Greenbaum, L.A.; Smith, J.M.; Gipson, D.S.; Filler, G.; Warady, B.A.; Martz, K.; Wong, C.S. Association between clinical risk factors and progression of chronic kidney disease in children. Clin. J. Am. Soc. Nephrol., 2010, 5(12), 2172-2179.
127. Baracco, R.; Saadeh, S.; Valentini, R.; Kapur, G.; Jain, A.; Mattoo, T.K. Iron deficiency in children with early chronic kidney disease. Pediatr. Nephrol., 2011, 26(11), 2077-2080.
128. Staples, A.O.; Wong, C.S.; Smith, J.M.; Gipson, D.S.; Filler, G.; Warady, B.A.; Martz, K.; Greenbaum, L.A. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2009, 4(1), 48-56.
129. Leonard, M.B.; Donaldson, L.A.; Ho, M.; Geary, D.F. A prospective cohort study of incident maintenance dialysis in children: an NAPRTC study. Kidney Int., 2003, 63(2), 744-755.
130. Warady, B.A.; Ho, M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr. Nephrol., 2003, 18(10), 1055-1062.
131. Frankenfield, D.L.; Neu, A.M.; Warady, B.A.; Fivush, B.A.; Johnson, C.A.; Brem, A.S. Anemia in pediatric hemodialysis patients: results from the 2001 ESRD Clinical Performance Measures Project. Kidney Int., 2003, 64(3), 1120-1124.
132. Chavers, B.M.; Roberts, T.L.; Herzog, C.A.; Collins, A.J.; St Peter, W.L. Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis pa-tients. Kidney Int., 2004, 65(1), 266-273.
133. Pruthi, R.; Maxwell, H.; Casula, A.; Braddon, F.; Lewis, M.; OBrien, C.; Stojanovic, J.; Tse, Y.; Inward, C.; Sinha, M.D. UK Renal Registry 16th annual report: chapter 13 clinical, haematological and biochemical parameters in patients receiving renal replacement therapy in paediatric cen-tres in the uk in 2012: national and centre-specific analyses. Nephron Clin. Pract., 2013, 125(1-4), 259-273.
134. Borzych-Duzalka, D.; Bilginer, Y.; Ha, I.S.; Bak, M.; Rees, L.; Cano, F.; Munarriz, R.L.; Chua, A.; Pesle, S.; Emre, S.; Urzykowska, A.; Quiroz, L.; Ruscasso, J.D.; White, C.; Pape, L.; Ramela, V.; Printza, N.; Vogel, A.; Kuzmanovska, D.; Simkova, E.; Müller-Wiefel, D.E.; Sander, A.; Warady, B.A.; Schaefer, F. Management of anemia in children re-ceiving chronic peritoneal dialysis. J. Am. Soc. Nephrol., 2013, 24(4), 665-676.
135. van Stralen, K.J.; Krischock, L.; Schaefer, F.; Verrina, E.; Groothoff, J.W.; Evans, J.; Heaf, J.; Ivanov, D.; Kostic, M.; Maringhini, S.; Podracká, L.; Printza, N.; Pundziene, B.; Reusz, G.S.; Vondrak, K.; Jager, K.J.; Tizard, E.J. Prevalence and predictors of the sub-target Hb level in children on dialysis. Nephrol. Dial. Transplant., 2012, 27(10), 3950-3957.
136. Łukaszyk, E.; Łukaszyk, M.; Koc-Zórawska, E.; Tobol-czyk, J.; Bodzenta-Łukaszyk, A.; Małyszko, J. Iron status and inflammation in early stages of chronic kidney disease. Kidney Blood Press. Res., 2015, 40(4), 366-373.
137. Boehm, M.; Riesenhuber, A.; Winkelmayer, W.C.; Ar-beiter, K.; Mueller, T.; Aufricht, C. Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr. Nephrol., 2007, 22(8), 1189-1193.
138. Gerson, A.C.; Butler, R.; Moxey-Mims, M.; Wentz, A.; Shinnar, S.; Lande, M.B.; Mendley, S.R.; Warady, B.A.; Furth, S.L.; Hooper, S.R. Neurocognitive outcomes in children with chronic kidney disease: Current findings and contemporary endeavors. Ment. Retard. Dev. Disabil. Res. Rev., 2006, 12(3), 208-215.
139. Eckardt, K.U.; Kim, J.; Kronenberg, F.; Aljama, P.; Anker, S.D.; Canaud, B.; Molemans, B.; Stenvinkel, P.; Schern-thaner, G.; Ireland, E.; Fouqueray, B.; Macdougall, I.C. Hemoglobin variability does not predict mortality in European hemodialysis patients. J. Am. Soc. Nephrol., 2010, 21(10), 1765-1775.
140. Bae, M.N.; Kim, S.H.; Kim, Y.O.; Jin, D.C.; Song, H.C.; Choi, E.J.; Kim, Y.L.; Kim, Y.S.; Kang, S.W.; Kim, N.H.; Yang, C.W.; Kim, Y.K. Association of erythropoietin-stimulating agent responsiveness with mortality in hemo-dialysis and peritoneal dialysis patients. PLoS One, 2015, 10(11), e0143348.
141. Rheault, M.N.; Molony, J.T.; Nevins, T.; Herzog, C.A.; Chavers, B.M. Hemoglobin of 12 g/dl and above is not as-sociated with increased cardiovascular morbidity in children on hemodialysis. Kidney Int., 2017, 91(1), 177-182.
142. Chang, H.C.; Chen, C.L.; Chiu, T.L.; Chen, S.I.; Yen, A.M.; Chen, T.H. Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis: analysis of 702 patients after 10-year follow-up. Public Health Nutr., 2009, 12(12), 2410-2415.
143. Morris, K.P.; Watson, S.; Reid, M.M.; Hamilton, P.J.; Coulthard, M.G. Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use? Pediatr. Nephrol., 1994, 8(1), 51-56.
144. Rocha, L.A.; Barreto, D.V.; Barreto, F.C.; Dias, C.B.; Moysés, R.; Silva, M.R.; Moura, L.A.; Draibe, S.A.; Jor-getti, V.; Carvalho, A.B.; Canziani, M.E. Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin. J. Am. Soc. Nephrol., 2009, 4(1), 105-109.
145. Weiss, G.; Theurl, I.; Eder, S.; Koppelstaetter, C.; Kurz, K.; Sonnweber, T.; Kobold, U.; Mayer, G. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur. J. Clin. Invest., 2009, 39(10), 883-890.
146. Mercadal, L.; Metzger, M.; Haymann, J.P.; Thervet, E.; Boffa, J.J.; Flamant, M.; Vrtovsnik, F.; Houillier, P.; Frois-sart, M.; Stengel, B. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One, 2014, 9(6), e99781.
147. Takasawa, K.; Takaeda, C.; Maeda, T.; Ueda, N. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis pa-tients. Nutrients, 2014, 7(1), 103-118.
148. Małyszko, J.; Małyszko, J.S.; Hryszko, T.; Pawlak, K.; Mysliwiec, M. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am. J. Nephrol., 2005, 25(6), 586-590.
149. Uehata, T.; Tomosugi, N.; Shoji, T.; Sakaguchi, Y.; Suzuki, A.; Kaneko, T.; Okada, N.; Yamamoto, R.; Nagasawa, Y.; Kato, K.; Isaka, Y.; Rakugi, H.; Tsubakihara, Y. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol. Dial. Transplant., 2012, 27(3), 1076-1083.
150. Bârsan, L.; Stanciu, A.; Stancu, S.; Capusa, C.; Bratescu, L.; Mandache, E.; Radu, E.; Mircescu, G. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia. Hematology, 2015, 20(9), 543-552.
151. Rumjon, A.; Sarafidis, P.; Brincat, S.; Musto, R.; Malyszko, J.; Bansal, S.S.; Macdougall, I.C. Serum hemojuvelin and hepcidin levels in chronic kidney disease. Am. J. Nephrol., 2012, 35(3), 295-304.
152. Sarafidis, P.A.; Rumjon, A.; Ackland, D.; MacLaughlin, H.L.; Bansal, S.S.; Brasse-Lagnel, C.; Macdougall, I.C. Obesity does not influence hepcidin and hemojuvelin levels in hemodialysis patients. Nephron Clin. Pract., 2013, 124(3-4), 159-166.
153. Malyszko, J.; Malyszko, J.S.; Levin-Iaina, N.; Koc-Zorawska, E.; Kozminski, P.; Mysliwiec, M. Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients? Int. Urol. Nephrol., 2012, 44(6), 1805-1811.
154. Lakhal, S.; Talbot, N.P.; Crosby, A.; Stoepker, C.; Town-send, A.R.; Robbins, P.A.; Pugh, C.W.; Ratcliffe, P.J.; Mole, D.R. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood, 2009, 113(7), 1555-1563.
155. Lukaszyk, E.; Lukaszyk, M.; Koc-Zorawska, E.; Bodzenta-Lukaszyk, A.; Malyszko, J. GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients. Int. Urol. Nephrol., 2016, 48(6), 839-844.
156. Bargenda, A.; Musiał, K.; Zwolinska, D. Epidermal growth factor, growth differentiation factor-15, and survivin as novel biocompatibility markers in children on chronic dialysis. Biomarkers, 2016, 21(8), 752-756.
157. Li, X.Y.; Ying, J.; Li, J.H.; Zhu, S.L.; Li, J.; Pai, P. Growth differentiation factor GDF-15 does not influence iron metabolism in stable chronic haemodialysis patients. Ann. Clin. Biochem., 2015, 52(Pt 3), 399-403.
158. Honda, H.; Kobayashi, Y.; Onuma, S.; Shibagaki, K.; Yuza, T.; Hirao, K.; Yamamoto, T.; Tomosugi, N.; Shibata, T. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One, 2016, 11(3), e0151601.
159. Atkinson, M.A.; Pierce, C.B.; Zack, R.M.; Barletta, G.M.; Yadin, O.; Mentser, M.; Warady, B.A.; Furth, S.L. Hemoglobin differences by race in children with CKD. Am. J. Kidney Dis., 2010, 55(6), 1009-1017.
160. Dmitrieva, O.; de Lusignan, S.; Macdougall, I.C.; Gallagher, H.; Tomson, C.; Harris, K.; Desombre, T.; Goldsmith, D. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol., 2013, 14, 24.
161. Iimori, S.; Naito, S.; Noda, Y.; Nishida, H.; Kihira, H.; Yui, N.; Okado, T.; Sasaki, S.; Uchida, S.; Rai, T. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study. Nephrology (Carlton), 2015, 20(9), 601-608.
162. Freburger, J.K.; Ng, L.J.; Bradbury, B.D.; Kshirsagar, A.V.; Brookhart, M.A. Changing patterns of anemia management in US hemodialysis patients. Am. J. Med., 2012, 125(9), 906-14.e9.
163. Ribeiro, S.; Belo, L.; Reis, F.; Santos-Silva, A. Iron therapy in chronic kidney disease: Recent changes, benefits and risks. Blood Rev., 2016, 30(1), 65-72.
164. Vaziri, N.D. Safety issues in iron treatment in CKD. Semin. Nephrol., 2016, 36(2), 112-118.
165. Albaramki, J.; Hodson, E.M.; Craig, J.C.; Webster, A.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev., 2012, 1, CD007857.
166. Rostoker, G.; Griuncelli, M.; Loridon, C.; Magna, T.; Machado, G.; Drahi, G.; Dahan, H.; Janklewicz, P.; Cohen, Y. Reassessment of iron biomarkers for prediction of dialysis iron overload: An MRI study. PLoS One, 2015, 10(7), e0132006.
167. Canavese, C.; Bergamo, D.; Ciccone, G.; Burdese, M.; Maddalena, E.; Barbieri, S.; Thea, A.; Fop, F. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol. Dial. Transplant., 2004, 19(6), 1564-1570.
168. Shoji, T.; Niihata, K.; Fukuma, S.; Fukuhara, S.; Akizawa, T.; Inaba, M. Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflam-mation. Clin. Exp. Nephrol., 2016 Aug 8, DOI: 10.1007/s10157-016-1317-1
169. Malovrh, M.; Hojs, N.; Premru, V. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoie-sis-stimulating agents. Artif. Organs, 2011, 35(1), 63-68.
170. Lenga, I.; Lok, C.; Marticorena, R.; Hunter, J.; Dacouris, N.; Goldstein, M. Role of oral iron in the management of long-term hemodialysis patients. Clin. J. Am. Soc. Nephrol., 2007, 2(4), 688-693.
171. Tsuchida, A.; Paudyal, B.; Paudyal, P.; Ishii, Y.; Hiromura, K.; Nojima, Y.; Komai, M. Effectiveness of oral iron to manage anemia in long-term hemodialysis patients with the use of ultrapure dialysate. Exp. Ther. Med., 2010, 1(5), 777-781.
172. Agarwal, R.; Kusek, J.W.; Pappas, M.K. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int., 2015, 88(4), 905-914.
173. Inrig, J.K.; Barnhart, H.X.; Reddan, D.; Patel, U.D.; Sapp, S.; Califf, R.M.; Singh, A.K.; Szczech, L.A. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am. J. Kidney Dis., 2012, 60(3), 390-401.
174. Besarab, A.; Bolton, W.K.; Browne, J.K.; Egrie, J.C.; Nis-senson, A.R.; Okamoto, D.M.; Schwab, S.J.; Goodkin, D.A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med., 1998, 339(9), 584-590.
175. Canavese, C.; Strippoli, G.F.; Bonomini, M.; Triolo, G. Haemoglobin targets for chronic kidney disease: guideline from the Italian Society of Nephrology. G. Ital. Nefrol., 2007, 24(Suppl. 37), S99-S106.
176. Lewis, M.; Shaw, J.; Reid, C.; Evans, J.; Webb, N.; Verrier-Jones, K. Aspects of anaemia management in children with established renal failure (chapter 15). Nephrol. Dial. Trans-plant., 2007, 22(Suppl. 7), vii181-vii183.
177. Thamer, M.; Zhang, Y.; Kshirsagar, O.; Cotter, D.J.; Kaufman, J.S. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database. Am. J. Kidney Dis., 2014, 64(5), 706-713.
178. Guerrero-Riscos, M.Á.; Montes-Delgado, R.; Seda-Guzmán, M.; Praena-Fernández, J.M. Erythropoietin resistance and survival in non-dialysis patients with stage 45 chronic kidney disease and heart disease. Nefrologia, 2012, 32(3), 343-352.
179. Wan, Q.; He, Y.; Zhang, W.; Wu, Q.; Xiong, Z. Prevalence and related factors of the absence of anemia among Chinese chronic hemodialysis patients: a multicenter cross-sectional study. Int. Urol. Nephrol., 2014, 46(8), 1651-1654.
180. Wetmore, J.B.; Peng, Y.; Monda, K.L.; Kats, A.M.; Kim, D.H.; Bradbury, B.D.; Collins, A.J.; Gilbertson, D.T. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis. Am. J. Nephrol., 2015, 41(4-5), 354-361.
181. Takasawa, K.; Tomosugi, N.; Takaeda, C.; Maeda, T.; Ueda, N. Regulation of hepcidin-25 by short-and long-acting rhEPO may be dependent on ferritin and predict the response to rhEPO in hemodialysis patients. Nephron Extra, 2014, 4(1), 55-63.
182. Kuriyama, S.; Tomonari, H.; Yoshida, H.; Hashimoto, T.; Kawaguchi, Y.; Sakai, O. Reversal of anemia by erythro-poietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron, 1997, 77(2), 176-185.
183. Gouva, C.; Nikolopoulos, P.; Ioannidis, J.P.; Siamopoulos, K.C. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int., 2004, 66(2), 753-760.
184. Hung, S.C.; Lin, Y.P.; Tarng, D.C. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years? J. Formos. Med. Assoc., 2014, 113(1), 3-10.
185. Yorgin, P.D.; Belson, A.; Sarwal, M.; Alexander, S.R. Sodium ferric gluconate therapy in renal transplant and renal failure patients. Pediatr. Nephrol., 2000, 15(3-4), 171-175.
186. Ruiz-Jaramillo, Mde.L.; Guízar-Mendoza, J.M.; Gutiérrez-Navarro, Mde.J.; Dubey-Ortega, L.A.; Amador-Licona, N. Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study. Pediatr. Nephrol., 2004, 19(1), 77-81.
187. Stancu, S.; Bârsan, L.; Stanciu, A.; Mircescu, G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin. J. Am. Soc. Nephrol., 2010, 5(3), 409-416.
188. Covic, A.; Mircescu, G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol. Dial. Transplant., 2010, 25(8), 2722-2730.
189. Urrechaga, E.; Boveda, O.; Aguayo, F.J.; de la Hera, P.; Muñoz, R.I.; Gallardo, I.; Escanero, J.F. Percentage of hypochromic erythrocytes and reticulocyte hemoglobin equivalent predictors of response to intravenous iron in hemodialysis patients. Int. J. Lab. Hematol., 2016, 38(4), 360-365.
190. Gaillard, C.A.; Bock, A.H.; Carrera, F.; Eckardt, K.U.; Van Wyck, D.B.; Bansal, S.S.; Cronin, M.; Meier, Y.; Larroque, S.; Roger, S.D.; Macdougall, I.C. Hepcidin response to iron therapy in patients with non-dialysis dependent CKD: An analysis of the FIND-CKD trial. PLoS One, 2016, 11(6), e0157063.
191. Tessitore, N.; Girelli, D.; Campostrini, N.; Bedogna, V.; Pietro Solero, G.; Castagna, A.; Melilli, E.; Mantovani, W.; De Matteis, G.; Olivieri, O.; Poli, A.; Lupo, A. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol. Dial. Transplant., 2010, 25(12), 3996-4002.
192. Drakou, A.; Margeli, A.; Theodorakopoulou, S.; Agrogian-nis, I.; Poziopoulos, C.; Papassotiriou, I.; Vlahakos, D.V. Assessment of serum bioactive hepcidin-25, soluble trans-ferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymal-tose. Blood Cells Mol. Dis., 2016, 59, 100-105.
193. Bonthuis, M.; van Stralen, K.J.; Verrina, E.; Groothoff, J.W.; Alonso Melgar, Á.; Edefonti, A.; Fischbach, M.; Mendes, P.; Molchanova, E.A.; Paripovic, D.; Peco-Antic, A.; Printza, N.; Rees, L.; Rubik, J.; Stefanidis, C.J.; Sinha, M.D.; Zagozdzon, I.; Jager, K.J.; Schaefer, F. Underweight, overweight and obesity in paediatric dialysis and renal transplant patients. Nephrol. Dial. Transplant., 2013, 28(Suppl. 4), iv195-iv204.
194. Ku, E.; Glidden, D.V.; Hsu, C.Y.; Portale, A.A.; Grimes, B.; Johansen, K.L. Association of body mass index with patient-centered outcomes in children with ESRD. J. Am. Soc. Nephrol., 2016, 27(2), 551-558.
195. Satirapoj, B.; Supasyndh, O.; Mayteedol, N.; Punpanich, D.; Chaiprasert, A.; Nata, N.; Ruangkanchanasetr, P.; Kan-janakul, I.; Choovichian, P. Obesity and its relation to chronic kidney disease: a population-based, cross-sectional study of a Thai army population and relatives. Nephrology (Carlton), 2013, 18(3), 229-234.
196. Arinsoy, T.; Deger, S.M.; Ates, K.; Altun, B.; Ecder, T.; Camsari, T.; Serdengecti, K.; Suleymanlar, G. Prevalence of chronic kidney disease in Turkish adults with obesity and metabolic syndrome: A Post Hoc analysis from chronic renal disease in Turkey study. J. Ren. Nutr., 2016, 26(6), 373-379.
197. Sanad, M.; Osman, M.; Gharib, A. Obesity modulate serum hepcidin and treatment outcome of iron deficiency anemia in children: a case control study. Ital. J. Pediatr., 2011, 37, 34.
198. Baumgartner, J.; Smuts, C.M.; Aeberli, I.; Malan, L.; Tjalsma, H.; Zimmermann, M.B. Overweight impairs efficacy of iron supplementation in iron-deficient South Afri-can children: a randomized controlled intervention. Int. J. Obes., 2013, 37(1), 24-30.
199. Susantitaphong, P.; Alqahtani, F.; Jaber, B.L. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am. J. Nephrol., 2014, 39(2), 130-141.
200. Majoni, S.W.; Ellis, J.A.; Hall, H.; Abeyaratne, A.; Lawton, P.D. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia. Hemodial. Int., 2014, 18(4), 740-750.
201. Valenti, L.; Valenti, G.; Como, G.; Santorelli, G.; Dongio-vanni, P.; Rametta, R.; Fracanzani, A.L.; Tavazzi, D.; Messa, P.G.; Fargion, S. HFE genotype influences erythro-poiesis support requirement in hemodialysis patients: a prospective study. Am. J. Nephrol., 2008, 28(2), 311-316.
202. Brown, M.C.; Gaffney, D.; Gemmell, C.; Oakes, E.; Morris, S.; Spooner, R.; Jardine, A.G.; Geddes, C.C. Hemochroma-tosis gene mutations and treatment of anemia in patients on hemodialysis. Hemodial. Int., 2009, 13(4), 460-466.
203. Pelusi, S.; Girelli, D.; Rametta, R.; Campostrini, N.; Alfieri, C.; Traglia, M.; Dongiovanni, P.; Como, G.; Toniolo, D.; Camaschella, C.; Messa, P.; Fargion, S.; Valenti, L. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrol., 2013, 14, 48.
204. Perícole, F.V.; Alves, M.A.; Saad, S.T.; Costa, F.F. Hemo-chromatosis (HFE) gene mutations in Brazilian chronic hemodialysis patients. Braz. J. Med. Biol. Res., 2005, 38(9), 1321-1324.
205. Nai, A.; Pagani, A.; Silvestri, L.; Campostrini, N.; Corbella, M.; Girelli, D.; Traglia, M.; Toniolo, D.; Camaschella, C. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood, 2011, 118(16), 4459-4462.
206. Sonnweber, T.; Theurl, I.; Seifert, M.; Schroll, A.; Eder, S.; Mayer, G.; Weiss, G. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol. Dial. Transplant., 2011, 26(3), 977-987.
207. Ribeiro, S.; Garrido, P.; Fernandes, J.; Rocha-Pereira, P.; Costa, E.; Belo, L.; Reis, F.; Santos-Silva, A. Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses. Biofactors, 2016, 42(3), 296-306.
208. Kakimoto-Shino, M.; Toya, Y.; Kuji, T.; Fujikawa, T.; Umemura, S. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythro-poietin receptor activator administration in hemodialysis pa-tients: a randomized study. Ther. Apher. Dial., 2014, 18(5), 421-426.
209. Morikami, Y.; Fujimori, A.; Okada, S.; Kumei, M.; Mizobuchi, N.; Sakai, M. Twice-monthly administration of a lower dose of epoetin β pegol can maintain adequate hemoglobin levels in hemodialysis patients. Ther. Apher. Dial., 2015, 19(2), 138-143.
210. Onuma, S.; Honda, H.; Kobayashi, Y.; Yamamoto, T.; Michihata, T.; Shibagaki, K.; Yuza, T.; Hirao, K.; Tomo-sugi, N.; Shibata, T. Effects of long-term erythropoiesis-stimulating agents on iron metabolism in patients on hemo-dialysis. Ther. Apher. Dial., 2015, 19(6), 582-589.
211. Icardi, A.; Paoletti, E.; De Nicola, L.; Mazzaferro, S.; Russo, R.; Cozzolino, M. Renal anaemia and EPO hypore-sponsiveness associated with vitamin D deficiency: the po-tential role of inflammation. Nephrol. Dial. Transplant., 2013, 28(7), 1672-1679.
212. Brandt, J.R.; Avner, E.D.; Hickman, R.O.; Watkins, S.L. Safety and efficacy of erythropoietin in children with chronic renal failure. Pediatr. Nephrol., 1999, 13(2), 143-147.
213. André, J.L.; Deschênes, G.; Boudailliez, B.; Broux, F.; Fischbach, M.; Gagnadoux, M.F.; Horen, B.; Lahoche-Manucci, A.; Macher, M.A.; Roussel, B.; Tsimaratos, M.; Loirat, C. Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure. Pediatr. Nephrol., 2007, 22(5), 708-714.
214. Waterschoot, M. Evaluation of response to various erythro-poiesisstimulating proteins using anemia management software. J. Ren. Care, 2007, 33(2), 78-82.
215. Kimachi, M.; Fukuma, S.; Yamazaki, S.; Yamamoto, Y.; Akizawa, T.; Akiba, T.; Saito, A.; Fukuhara, S. Minor elevation in c-reactive protein levels predicts incidence of erythropoiesis-stimulating agent hyporesponsiveness among hemodialysis patients. Nephron, 2015, 131(2), 123-130.
216. Lestz, R.M.; Fivush, B.A.; Atkinson, M.A. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr. Nephrol., 2014, 29(10), 2021-2028.
217. Costa, E.; Pereira, B.J.; Rocha-Pereira, P.; Rocha, S.; Reis, F.; Castro, E.; Teixeira, F.; Miranda, V.; do Sameiro Faria, M.; Loureiro, A.; Quintanilha, A.; Belo, L.; Santos-Silva, A. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am. J. Nephrol., 2008, 28(4), 677-683.
218. Merchant, M.L.; Gaweda, A.E.; Dailey, A.J.; Wilkey, D.W.; Zhang, X.; Rovin, B.H.; Klein, J.B.; Brier, M.E. On-costatin M receptor β and cysteine/histidine-rich 1 are bio-markers of the response to erythropoietin in hemodialysis patients. Kidney Int., 2011, 79(5), 546-554.
219. Kato, A.; Tsuji, T.; Luo, J.; Sakao, Y.; Yasuda, H.; Hishida, A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am. J. Nephrol., 2008, 28(1), 115-121.
220. Ashby, D.R.; Gale, D.P.; Busbridge, M.; Murphy, K.G.; Duncan, N.D.; Cairns, T.D.; Taube, D.H.; Bloom, S.R.; Tam, F.W.; Chapman, R.S.; Maxwell, P.H.; Choi, P. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int., 2009, 75(9), 976-981.
221. Malyszko, J.; Malyszko, J.S.; Mysliwiec, M. Hyporespon-siveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation. Ren. Fail., 2009, 31(7), 544-548.
222. Caliskan, Y.; Yelken, B.; Ozkok, A.; Gorgulu, N.; Yazici, H.; Telci, A.; Yildiz, A. Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C. BMC Neph-rol., 2012, 13, 56.
223. van der Putten, K.; Jie, K.E.; van den Broek, D.; Kraaijen-hagen, R.J.; Laarakkers, C.; Swinkels, D.W.; Braam, B.; Gaillard, C.A. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur. J. Heart Fail., 2010, 12(9), 943-950.
224. Malyszko, J.; Koc-Zorawska, E.; Levin-Iaina, N.; Slotki, I.; Matuszkiewicz-Rowinska, J.; Glowinska, I.; Malyszko, J.S. Iron metabolism in hemodialyzed patients-a story half told? Arch. Med. Sci., 2014, 10(6), 1117-1122.
225. Gammella, E.; Diaz, V.; Recalcati, S.; Buratti, P.; Samaja, M.; Dey, S.; Noguchi, C.T.; Gassmann, M.; Cairo, G. Erythropoietins inhibiting impact on hepcidin expression occurs indirectly. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2015, 308(4), R330-R335.
226. Ribeiro, S.; Garrido, P.; Fernandes, J.; Rocha, S.; Rocha-Pereira, P.; Costa, E.; Belo, L.; Reis, F.; Santos-Silva, A. Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. Blood Cells Mol. Dis., 2016, 59, 63-70.
227. Bellinghieri, G.; Condemi, C.G.; Saitta, S.; Trifirò, G.; Gangemi, S.; Savica, V.; Buemi, M.; Santoro, D. Erythro-poiesis-stimulating agents: dose and mortality risk. J. Ren. Nutr., 2015, 25(2), 164-168.
228. Bamgbola, O.F. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int., 2011, 80(5), 464-474.
229. Cui, Y.; Wu, Q.; Zhou, Y. Iron-refractory iron deficiency anemia: new molecular mechanisms. Kidney Int., 2009, 76(11), 1137-1141.
230. Besarab, A.; Coyne, D.W. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat. Rev. Nephrol., 2010, 6(12), 699-710.
231. Locatelli, F.; Andrulli, S.; Memoli, B.; Maffei, C.; Del Vec-chio, L.; Aterini, S.; De Simone, W.; Mandalari, A.; Brunori, G.; Amato, M.; Cianciaruso, B.; Zoccali, C. Nutri-tional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol. Dial. Transplant., 2006, 21(4), 991-998.
232. Hu, J.P.; Cheng, X.; Xu, X.F.; Yu, G.J.; Luo, F.; Zhang, G.S.; Yang, N.; Shen, P.; Yan, X.Y. Reactivity of patients with maintenance hemodialysis to erythropoietin in the treatment of renal anemia. J. Biol. Regul. Homeost. Agents, 2016, 30(2), 535-540.
233. Kato, A.; Hamada, M.; Suzuki, T.; Maruyama, T.; Maru-yama, Y.; Hishida, A. Effect of weekly or successive iron supplementation on erythropoietin doses in patients receiving hemodialysis. Nephron, 2001, 89(1), 110-112.
234. Gastaldello, K.; Vereerstraeten, A.; Nzame-Nze, T.; Van-herweghem, J.L.; Tielemans, C. Resistance to erythro-poietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol. Dial. Transplant., 1995, 10(Suppl. 6), 44-47.
235. do Sameiro-Faria, M.; Ribeiro, S.; Rocha-Pereira, P.; Fer-nandes, J.; Reis, F.; Bronze-da-Rocha, E.; Miranda, V.; Quintanilha, A.; Costa, E.; Belo, L.; Santos-Silva, A. Body mass index and resistance to recombinant human erythro-poietin therapy in maintenance hemodialysis patients. Ren. Fail., 2013, 35(10), 1392-1398.
236. Malyszko, J.; Malyszko, J.S.; Kozminski, P.; Mysliwiec, M. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin. Ren. Fail., 2009, 31(10), 876-883.
237. Panichi, V.; Scatena, A.; Rosati, A.; Giusti, R.; Ferro, G.; Malagnino, E.; Capitanini, A.; Piluso, A.; Conti, P.; Bern-abini, G.; Migliori, M.; Caiani, D.; Tetta, C.; Casani, A.; Betti, G.; Pizzarelli, F. High-volume online haemodiafiltra-tion improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrol. Dial. Transplant., 2015, 30(4), 682-689.
238. Seeherunvong, W.; Abitbol, C.L.; Chandar, J.; Zilleruelo, G.; Freundlich, M. Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J. Pediatr., 2009, 154(6), 906-11.e1.
239. Kumar, J.; McDermott, K.; Abraham, A.G.; Friedman, L.A.; Johnson, V.L.; Kaskel, F.J.; Furth, S.L.; Warady, B.A.; Portale, A.A.; Melamed, M.L. Prevalence and corre-lates of 25-hydroxyvitamin D deficiency in the chronic kidney disease in children (CKiD) cohort. Pediatr. Nephrol., 2016, 31(1), 121-129.
240. Shroff, R.; Egerton, M.; Bridel, M.; Shah, V.; Donald, A.E.; Cole, T.J.; Hiorns, M.P.; Deanfield, J.E.; Rees, L. A bi-modal association of vitamin D levels and vascular disease in children on dialysis. J. Am. Soc. Nephrol., 2008, 19(6), 1239-1246.
241. Górriz, J.L. Molina, P.; Bover, J.; Barril, G.; Martín-de Francisco, A.L.; Caravaca, F.; Hervás, J.; Piñera, C.; Es-cudero, V.; Molinero, L.M.; en nombre de los investi-gadores del estudio OSERCE. Characteristics of bone mineral metabolism in patients with stage 35 chronic kidney disease not on dialysis: results of the OSERCE study. Ne-frologia, 2013, 33(1), 46-60.
242. Damasiewicz, M.J.; Magliano, D.J.; Daly, R.M.; Gagnon, C.; Lu, Z.X.; Sikaris, K.A.; Ebeling, P.R.; Chadban, S.J.; Atkins, R.C.; Kerr, P.G.; Shaw, J.E.; Polkinghorne, K.R. Serum 25-hydroxyvitamin D deficiency and the 5-year incidence of CKD. Am. J. Kidney Dis., 2013, 62(1), 58-66.
243. Bindal, M.E.; Taskapan, H. Hypovitaminosis D and insulin resistance in peritoneal dialysis patients. Int. Urol. Neph-rol., 2011, 43(2), 527-534.
244. Taskapan, H.; Ersoy, F.F.; Passadakis, P.S.; Tam, P.; Memmos, D.E.; Katopodis, K.P.; Ozener, C.; Akcicek, F.; Camsari, T.; Ates, K.; Ataman, R.; Vlachojannis, J.G.; Dombros, N.A.; Utas, C.; Akpolat, T.; Bozfakioglu, S.; Wu, G.; Karayaylali, I.; Arinsoy, T.; Stathakis, C.P.; Yavuz, M.; Tsakiris, D.J.; Dimitriades, A.D.; Yilmaz, M.E.; Gültekin, M.; Oreopoulos, D.G. Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin. Nephrol., 2006, 66(4), 247-255.
245. Ahmadi, F.; Damghani, S.; Lessan-Pezeshki, M.; Razeghi, E.; Maziar, S.; Mahdavi-Mazdeh, M. Association of low vitamin D levels with metabolic syndrome in hemodialysis patients. Hemodial. Int., 2016, 20(2), 261-269.
246. Wolf, M.; Shah, A.; Gutierrez, O.; Ankers, E.; Monroy, M.; Tamez, H.; Steele, D.; Chang, Y.; Camargo, C.A., Jr; Tonelli, M.; Thadhani, R. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int., 2007, 72(8), 1004-1013.
247. Ureña-Torres, P.; Metzger, M.; Haymann, J.P.; Karras, A.; Boffa, J.J.; Flamant, M.; Vrtovsnik, F.; Gauci, C.; Froissart, M.; Houillier, P.; Stengel, B. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD. Am. J. Kidney Dis., 2011, 58(4), 544-553.
248. Atkinson, M.A.; Melamed, M.L.; Kumar, J.; Roy, C.N.; Miller, E.R., III; Furth, S.L.; Fadrowski, J.J. Vitamin D, race, and risk for anemia in children. J. Pediatr., 2014, 164(1), 153-158.e1.
249. Rianthavorn, P.; Boonyapapong, P. Ergocalciferol de-creases erythropoietin resistance in children with chronic kidney disease stage 5. Pediatr. Nephrol., 2013, 28(8), 1261-1266.
250. Zughaier, S.M.; Alvarez, J.A.; Sloan, J.H.; Konrad, R.J.; Tangpricha, V. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J. Clin. Transl. En-docrinol., 2014, 1(1), 19-25.
251. Riccio, E.; Sabbatini, M.; Bruzzese, D.; Capuano, I.; Migli-accio, S.; Andreucci, M.; Pisani, A. Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. PLoS One, 2015, 10(3), e0118174.
252. Afsar, B.; Agca, E.; Turk, S. Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacal-cet, or paricalcitol. J. Clin. Pharmacol., 2015, 55(11), 1280-1285.
253. Carvalho, C.; Isakova, T.; Collerone, G.; Olbina, G.; Wolf, M.; Westerman, M.; Gutiérrez, O.M. Hepcidin and disordered mineral metabolism in chronic kidney disease. Clin. Nephrol., 2011, 76(2), 90-98.
254. Bacchetta, J.; Zaritsky, J.J.; Sea, J.L.; Chun, R.F.; Lisse, T.S.; Zavala, K.; Nayak, A.; Wesseling-Perry, K.; Wester-man, M.; Hollis, B.W.; Salusky, I.B.; Hewison, M. Sup-pression of iron-regulatory hepcidin by vitamin D. J. Am. Soc. Nephrol., 2014, 25(3), 564-572.
255. Cengiz, N.; Baskin, E.; Sezgin, N.; Agras, P.; Haberal, M. Oxidative stress in children on hemodialysis: value of autoantibodies against oxidized low-density lipoprotein. Pediatr. Nephrol., 2009, 24(2), 387-393.
256. Nehus, E.; Furth, S.; Warady, B.; Mitsnefes, M. Correlates of resistin in children with chronic kidney disease: the chronic kidney disease in children cohort. J. Pediatr., 2012, 161(2), 276-280.
257. Zhang, X.; Rovin, B.H. Hepcidin expression by human monocytes in response to adhesion and pro-inflammatory cytokines. Biochim. Biophys. Acta., 2010, 1800(12), 1262-1267.
258. Memoli, B.; Salerno, S.; Procino, A.; Postiglione, L.; Mo-relli, S.; Sirico, M.L.; Giordano, F.; Ricciardone, M.; Drioli, E.; Andreucci, V.E.; Bartoli, L.D. A translational approach to micro-inflammation in end-stage renal disease: molecular effects of low levels of interleukin-6. Clin. Sci., 2010, 119(4), 163-174.
259. Battistella, M.; Richardson, R.M.; Bargman, J.M.; Chan, C.T. Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease. Clin. Nephrol., 2011, 76(2), 99-103.
260. Belsha, C.W.; Berry, P.L. Effect of hyperparathyroidism on response to erythropoietin in children on dialysis. Pediatr. Nephrol., 1998, 12(4), 298-303.
261. Drüeke, T.B.; Eckardt, K.U. Role of secondary hyperpara-thyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol. Dial. Transplant., 2002, 17(Suppl. 5), 28-31.
262. Soylemezoglu, O.; Duzova, A.; Yalçinkaya, F.; Arinsoy, T.; Süleymanlar, G. Chronic renal disease in children aged 518 years: a population-based survey in Turkey, the CREDIT-C study. Nephrol. Dial. Transplant., 2012, 27(Suppl. 3), iii146-iii151.
263. Wilson, A.C.; Schneider, M.F.; Cox, C.; Greenbaum, L.A.; Saland, J.; White, C.T.; Furth, S.; Warady, B.A.; Mitsnefes, M.M. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2011, 6(12), 2759-2765.
264. Bello, A.; Padwal, R.; Lloyd, A.; Hemmelgarn, B.; Klaren-bach, S.; Manns, B.; Tonelli, M. Using linked administrative data to study periprocedural mortality in obesity and chronic kidney disease (CKD). Nephrol. Dial. Transplant., 2013, 28(Suppl. 4), iv57-iv64.
265. Titze, S.; Schmid, M.; Köttgen, A.; Busch, M.; Floege, J.; Wanner, C.; Kronenberg, F.; Eckardt, K.U. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol. Dial. Transplant., 2015, 30(3), 441-451.
266. Chen, H.M.; Shen, W.W.; Ge, Y.C.; Zhang, Y.D.; Xie, H.L.; Liu, Z.H. The relationship between obesity and diabetic nephropathy in China. BMC Nephrol., 2013, 14, 69.
267. Jung, C.H.; Lee, M.J.; Kang, Y.M.; Hwang, J.Y.; Kim, E.H.; Park, J.Y.; Kim, H.K.; Lee, W.J. The risk of chronic kidney disease in a metabolically healthy obese population. Kidney Int., 2015, 88(4), 843-850.
268. Chang, Y.; Ryu, S.; Choi, Y.; Zhang, Y.; Cho, J.; Kwon, M.J.; Hyun, Y.Y.; Lee, K.B.; Kim, H.; Jung, H.S.; Yun, K.E.; Ahn, J.; Rampal, S.; Zhao, D.; Suh, B.S.; Chung, E.C.; Shin, H.; Pastor-Barriuso, R.; Guallar, E. Metaboli-cally healthy obesity and development of chronic kidney disease: A Cohort study. Ann. Intern. Med., 2016, 164(5), 305-312.
269. Blaslov, K.; Bulum, T.; Duvnjak, L. Waist-to-height ratio is independently associated with chronic kidney disease in overweight type 2 diabetic patients. Endocr. Res., 2015, 40(4), 194-198.
270. del Giudice, E.M.; Santoro, N.; Amato, A.; Brienza, C.; Calabrò, P.; Wiegerinck, E.T.; Cirillo, G.; Tartaglione, N.; Grandone, A.; Swinkels, D.W.; Perrone, L. Hepcidin in obese children as a potential mediator of the association between obesity and iron deficiency. J. Clin. Endocrinol. Me-tab., 2009, 94(12), 5102-5107.
271. Sarafidis, P.A.; Rumjon, A.; MacLaughlin, H.L.; Macdou-gall, I.C. Obesity and iron deficiency in chronic kidney disease: the putative role of hepcidin. Nephrol. Dial. Transplant., 2012, 27(1), 50-57.
272. Amato, A.; Santoro, N.; Calabrò, P.; Grandone, A.; Swinkels, D.W.; Perrone, L.; del Giudice, E.M. Effect of body mass index reduction on serum hepcidin levels and iron status in obese children. Int. J. Obes., 2010, 34(12), 1772-1774.
273. Aigner, E.; Feldman, A.; Datz, C. Obesity as an emerging risk factor for iron deficiency. Nutrients, 2014, 6(9), 3587-3600.
274. Rossert, J.; Gassmann-Mayer, C.; Frei, D.; McClellan, W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol. Dial. Transplant., 2007, 22(3), 794-800.
275. Vega, A.; Ruiz, C.; Abad, S.; Quiroga, B.; Velázquez, K.; Yuste, C.; Aragoncillo, I.; López Gómez, J.M. Body composition affects the response to erythropoiesis-stimulating agents in patients with chronic kidney disease in dialysis. Ren. Fail., 2014, 36(7), 1073-1077.
276. Teplan, V., Jr; Vyhnánek, F.; Gürlich, R.; Haluzík, M.; Racek, J.; Vyhnankova, I.; Stollová, M.; Teplan, V. Increased proinflammatory cytokine production in adipose tissue of obese patients with chronic kidney disease. Wien. Klin. Wochenschr., 2010, 122(15-16), 466-473.
277. Bekri, S.; Gual, P.; Anty, R.; Luciani, N.; Dahman, M.; Ramesh, B.; Iannelli, A.; Staccini-Myx, A.; Casanova, D.; Ben Amor, I.; Saint-Paul, M.C.; Huet, P.M.; Sadoul, J.L.; Gugenheim, J.; Srai, S.K.; Tran, A.; Le Marchand-Brustel, Y. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroen-terology, 2006, 131(3), 788-796.
278. Andrade-Oliveira, V.; Câmara, N.O.; Moraes-Vieira, P.M. Adipokines as drug targets in diabetes and underlying disturbances. J. Diabetes Res., 2015 Apr 8; 2015, 681612.
279. Luciani, N.; Brasse-Lagnel, C.; Poli, M.; Anty, R.; Lesueur, C.; Cormont, M.; Laquerriere, A.; Folope, V.; LeMarchand-Brustel, Y.; Gugenheim, J.; Gual, P.; Tran, A.; Bekri, S. Hemojuvelin: a new link between obesity and iron homeo-stasis. Obesity (Silver Spring), 2011, 19(8), 1545-1551.
280. Nehus, E.; Furth, S.; Warady, B.; Mitsnefes, M. Correlates of leptin in children with chronic kidney disease. J. Pedi-atr., 2014, 165(4), 825-829.
281. Mitsnefes, M.; Kartal, J.; Khoury, P.; Daniels, S. Adi-ponectin in children with chronic kidney disease: role of adiposity and kidney dysfunction. Clin. J. Am. Soc. Neph-rol., 2007, 2(1), 46-50.
282. Eleftheriadis, T.; Pissas, G.; Remoundou, M.; Antoniadi, G.; Liakopoulos, V.; Stefanidis, I. Increased visfatin in hemodialysis patients is associated with decreased demands for recombinant human erythropoietin. Ren. Fail., 2013, 35(10), 1399-1403.
283. Pihan-Le Bars, F.; Bonnet, F.; Loréal, O.; Le Loupp, A.G.; Ropert, M.; Letessier, E.; Prieur, X.; Bach, K.; Deugnier, Y.; Fromenty, B.; Cariou, B. Indicators of iron status are correlated with adiponectin expression in adipose tissue of patients with morbid obesity. Diabetes Metab., 2016, 42(2), 105-111.
284. Abe, M.; Okada, K.; Maruyama, T.; Maruyama, N.; Ma-tsumoto, K.; Soma, M. Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemo-dialysis patients with diabetes. Int. J. Artif. Organs, 2011, 34(1), 16-25.
285. Chung, B.; Matak, P.; McKie, A.T.; Sharp, P. Leptin increases the expression of the iron regulatory hormone hep-cidin in HuH7 human hepatoma cells. J. Nutr., 2007, 137(11), 2366-2370.
286. Dongiovanni, P.; Ruscica, M.; Rametta, R.; Recalcati, S.; Steffani, L.; Gatti, S.; Girelli, D.; Cairo, G.; Magni, P.; Far-gion, S.; Valenti, L. Dietary iron overload induces visceral adipose tissue insulin resistance. Am. J. Pathol., 2013, 182(6), 2254-2263.
287. Vlahakos, D.V.; Marathias, K.P.; Madias, N.E. The role of the renin-angiotensin system in the regulation of erythro-poiesis. Am. J. Kidney Dis., 2010, 56(3), 558-565.
288. Miyachi, H.; Kobayashi, Y.; Relja, B.; Fujita, N.; Iwasa, M.; Gabazza, E.C.; Takei, Y. Effect of suppressor of cyto-kine signaling on hepcidin production in hepatitis C virus replicon cells. Hepatol. Res., 2011, 41(4), 364-374.
289. Ishizaka, N.; Saito, K.; Furuta, K.; Matsuzaki, G.; Koike, K.; Noiri, E.; Nagai, R. Angiotensin II-induced regulation of the expression and localization of iron metabolism-related genes in the rat kidney. Hypertens. Res., 2007, 30(2), 195-202.
290. Tajima, S.; Ikeda, Y.; Enomoto, H.; Imao, M.; Horinouchi, Y.; Izawa-Ishizawa, Y.; Kihira, Y.; Miyamoto, L.; Ishi-zawa, K.; Tsuchiya, K.; Tamaki, T. Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice. Eur. J. Nutr., 2015, 54(5), 709-719.
291. Akchurin, O.; Sureshbabu, A.; Doty, S.B.; Zhu, Y.S.; Patino, E.; Cunningham-Rundles, S.; Choi, M.E.; Boskey, A.; Rivella, S. Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease. Am. J. Physiol. Renal Physiol., 2016, 311(5), F877-F889.
292. van der Weerd, N.C.; Grooteman, M.P.; Bots, M.L.; van den Dorpel, M.A.; den Hoedt, C.H.; Mazairac, A.H.; Nubé, M.J.; Penne, E.L.; Wetzels, J.F.; Wiegerinck, E.T.; Swinkels, D.W.; Blankestijn, P.J.; Ter Wee, P.M. Hepcidin-25 is related to cardiovascular events in chronic haemo-dialysis patients. Nephrol. Dial. Transplant., 2013, 28(12), 3062-3071.
293. Ulu, S.M.; Yuksel, S.; Altuntas, A.; Kacar, E.; Ahsen, A.; Altug, A.; Celik, S.; Sezer, M.T. Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients. Int. Urol. Nephrol., 2014, 46(12), 2409-2414.
294. Kuragano, T.; Itoh, K.; Shimonaka, Y.; Kida, A.; Furuta, M.; Kitamura, R.; Yahiro, M.; Nanami, M.; Otaki, Y.; Hasuike, Y.; Nonoguchi, H.; Nakanishi, T. Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol. Dial. Transplant., 2011, 26(8), 2663-2667.
295. Xie, X.; Liu, Y.; Perkovic, V.; Li, X.; Ninomiya, T.; Hou, W.; Zhao, N.; Liu, L.; Lv, J.; Zhang, H.; Wang, H. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A Bayesian network meta-analysis of randomized clinical trials. Am. J. Kidney Dis., 2016, 67(5), 728-741.
296. Okazaki, M.; Komatsu, M.; Kawaguchi, H.; Tsuchiya, K.; Nitta, K. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purif., 2014, 37(2), 106-112.
297. Walker, V.J.; Agarwal, A. Targeting iron homeostasis in acute kidney injury. Semin. Nephrol., 2016, 36(1), 62-70.
298. Young, G.H.; Huang, T.M.; Wu, C.H.; Lai, C.F.; Hou, C.C.; Peng, K.Y.; Liang, C.J.; Lin, S.L.; Chang, S.C.; Tsai, P.R.; Wu, K.D.; Wu, V.C.; Ko, W.J. Hemojuvelin modulates iron stress during acute kidney injury: improved by furin inhibitor. Antioxid. Redox Signal., 2014, 20(8), 1181-1194.
299. Schaalan, M.F.; Mohamed, W.A. Determinants of hepcidin levels in sepsis-associated acute kidney injury: Impact on pAKT/PTEN pathways? J. Immunotoxicol., 2016, 13(5), 751-757.
300. Ho, J.; Reslerova, M.; Gali, B.; Gao, A.; Bestland, J.; Rush, D.N.; Nickerson, P.W.; Rigatto, C. Urinary hepcidin-25 and risk of acute kidney injury following cardiopulmonary by-pass. Clin. J. Am. Soc. Nephrol., 2011, 6(10), 2340-2346.
301. van Swelm, R.P.; Wetzels, J.F.; Verweij, V.G.; Laarakkers, C.M.; Pertijs, J.C.; van der Wijst, J.; Thévenod, F.; Ma-sereeuw, R.; Swinkels, D.W. Renal handling of circulating and renal-synthesized hepcidin and its protective effects against hemoglobin-mediated kidney injury. J. Am. Soc. Nephrol., 2016, 27(9), 2720-2732.
302. Zager, R.A.; Johnson, A.C.; Frostad, K.B. Combined iron sucrose and protoporphyrin treatment protects against ischemic and toxin-mediated acute renal failure. Kidney Int., 2016, 90(1), 67-76.
303. Veuthey, T.; DAnna, M.C.; Roque, M.E. Role of the kidney in iron homeostasis: renal expression of Prohepcidin, Fer-roportin, and DMT1 in anemic mice. Am. J. Physiol. Renal Physiol., 2008, 295(4), F1213-F1221.
304. Moulouel, B.; Houamel, D.; Delaby, C.; Tchernitchko, D.; Vaulont, S.; Letteron, P.; Thibaudeau, O.; Puy, H.; Gouya, L.; Beaumont, C.; Karim, Z. Hepcidin regulates intrarenal iron handling at the distal nephron. Kidney Int., 2013, 84(4), 756-766.
305. Shah, S.V.; Rajapurkar, M.M.; Baliga, R. The role of catalytic iron in acute kidney injury. Clin. J. Am. Soc. Nephrol., 2011, 6(10), 2329-2331.
306. Dominguez, J.H.; Liu, Y.; Kelly, K.J. Renal iron overload in rats with diabetic nephropathy. Physiol. Rep., 2015, 3(12), e12654.
307. Gao, W.; Li, X.; Gao, Z.; Li, H. Iron increases diabetes-induced kidney injury and oxidative stress in rats. Biol. Trace Elem. Res., 2014, 160(3), 368-375.
308. Zhou, C.; He, X.; Xue, D.; Xu, N. Elevated expression of hepcidin post-renal ischemia reperfusion injury. Acta Bio-chim. Biophys. Sin. (Shanghai), 2013, 45(4), 342-344.
309. Scindia, Y.; Dey, P.; Thirunagari, A.; Liping, H.; Rosin, D.L.; Floris, M.; Okusa, M.D.; Swaminathan, S. Hepcidin mitigates renal ischemia-reperfusion injury by modulating systemic iron homeostasis. J. Am. Soc. Nephrol., 2015, 26(11), 2800-2814.
310. Mohammed, M.F.; Belal, D.; Bakry, S.; Marie, M.A.; Rashed, L.; Eldin, R.E.; El-Hamid, S.A. A study of hep-cidin and monocyte chemoattractant protein-1 in Egyptian females with systemic lupus erythematosus. J. Clin. Lab. Anal., 2014, 28(4), 306-309.
311. Zhang, X.; Nagaraja, H.N.; Nadasdy, T.; Song, H.; McKin-ley, A.; Prosek, J.; Kamadana, S.; Rovin, B.H. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int., 2012, 81(4), 401-406.
312. Dendooven, A.; van Oostrom, O.; van der Giezen, D.M.; Leeuwis, J.W.; Snijckers, C.; Joles, J.A.; Robertson, E.J.; Verhaar, M.C.; Nguyen, T.Q.; Goldschmeding, R. Loss of endogenous bone morphogenetic protein-6 aggravates renal fibrosis. Am. J. Pathol., 2011, 178(3), 1069-1079.
313. Yamada, S.; Nakamura, J.; Asada, M.; Takase, M.; Ma-tsusaka, T.; Iguchi, T.; Yamada, R.; Tanaka, M.; Higashi, A.Y.; Okuda, T.; Asada, N.; Fukatsu, A.; Kawachi, H.; Graf, D.; Muso, E.; Kita, T.; Kimura, T.; Pastan, I.; Economides, A.N.; Yanagita, M. Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury. PLoS One, 2014, 9(2), e89135.
314. Yan, J.; Yang, S.; Zhang, J.; Zhai, C.; Zhu, T. BMP6 attenuates oxidant injury in HK-2 cells via Smad-dependent HO-1 induction. Free Radic. Biol. Med., 2009, 46(9), 1275-1282.
315. Gong, J.; Du, F.; Qian, Z.M.; Luo, Q.Q.; Sheng, Y.; Yung, W.H.; Xu, Y.X.; Ke, Y. Pre-treatment of rats with ad-hepcidin prevents iron-induced oxidative stress in the brain. Free Radic. Biol. Med., 2016, 90, 126-132.
316. Maruyama, Y.; Yokoyama, K.; Yamamoto, H.; Nakayama, M.; Hosoya, T. Do serum hepcidin-25 levels correlate with oxidative stress in patients with chronic kidney disease not receiving dialysis? Clin. Nephrol., 2012, 78(4), 281-286.
317. Hirata, M.; Tashiro, Y.; Aizawa, K.; Kawasaki, R.; Shimonaka, Y.; Endo, K. Epoetin β pegol alleviates oxida-tive stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats. Physiol. Rep., 2015, 3(12), e12637.
318. Rudnicki, M.; Perco, P.; Enrich, J.; Eder, S.; Heininger, D.; Bernthaler, A.; Wiesinger, M.; Sarközi, R.; Noppert, S.J.; Schramek, H.; Mayer, B.; Oberbauer, R.; Mayer, G. Hy-poxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab. Invest., 2009, 89(3), 337-346.
319. Donderski, R.; Szczepanek, J.; Domagalski, K.; Tretyn, A.; Korenkiewicz, J.; Marszałek, A.; Szymanski, A.; Wolski, Z.; Odrowaz-Sypniewska, G.; Manitius, J. Analysis of relative expression level of VEGF (vascular endothelial growth factor), HIF-1α (hypoxia inducible factor 1α) and CTGF (connective tissue growth factor) genes in chronic glomeru-lonephritis (CGN) patients. Kidney Blood Press. Res., 2013, 38(1), 83-91.
320. Garrido, P.; Ribeiro, S.; Fernandes, J.; Vala, H.; Rocha-Pereira, P.; Bronze-da-Rocha, E.; Belo, L.; Costa, E.; San-tos-Silva, A.; Reis, F. Resistance to recombinant human erythropoietin therapy in a rat model of chronic kidney disease associated anemia. Int. J. Mol. Sci., 2015, 17(1), E28.
321. Ruiz-Jaramillo, Mde.L.; Guízar-Mendoza, J.M.; Amador-Licona, N.; Gutiérrez-Navarro, Mde.J.; Hernández-González, M.A.; Dubey-Ortega, L.A.; Solorio-Meza, S.E. Iron overload as cardiovascular risk factor in children and adolescents with renal disease. Nephrol. Dial. Transplant., 2011, 26(10), 3268-3273.
322. Canavese, C.; Bergamo, D.; Ciccone, G.; Longo, F.; Fop, F.; Thea, A.; Martina, G.; Piga, A. Validation of serum fer-ritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int., 2004, 65(3), 1091-1098.
323. Kletzmayr, J.; Hörl, W.H. Iron overload and cardiovascular complications in dialysis patients. Nephrol. Dial. Transplant., 2002, 17(Suppl. 2), 25-29.
324. Poli, M.; Asperti, M.; Ruzzenenti, P.; Regoni, M.; Arosio, P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front. Pharmacol., 2014, 5, 86.
325. Alkhateeb, A.A.; Buckett, P.D.; Gardeck, A.M.; Kim, J.; Byrne, S.L.; Fraenkel, P.G.; Wessling-Resnick, M. The small molecule ferristatin II induces hepatic hepcidin expression in vivo and in vitro. Am. J. Physiol. Gastrointest. Liver Physiol., 2015, 308(12), G1019-G1026.
326. Ramos, E.; Ruchala, P.; Goodnough, J.B.; Kautz, L.; Preza, G.C.; Nemeth, E.; Ganz, T. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood, 2012, 120(18), 3829-3836.
327. Schmidt, P.J.; Fleming, M.D. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches. Hematol. Oncol. Clin. North Am., 2014, 28(2), 387-401.
328. Fung, E.; Sugianto, P.; Hsu, J.; Damoiseaux, R.; Ganz, T.; Nemeth, E. High-throughput screening of small molecules identifies hepcidin antagonists. Mol. Pharmacol., 2013, 83(3), 681-690.
329. Steinbicker, A.U.; Sachidanandan, C.; Vonner, A.J.; Yusuf, R.Z.; Deng, D.Y.; Lai, C.S.; Rauwerdink, K.M.; Winn, J.C.; Saez, B.; Cook, C.M.; Szekely, B.A.; Roy, C.N.; Seehra, J.S.; Cuny, G.D.; Scadden, D.T.; Peterson, R.T.; Bloch, K.D.; Yu, P.B. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood, 2011, 117(18), 4915-4923.
330. Theurl, I.; Schroll, A.; Sonnweber, T.; Nairz, M.; Theurl, M.; Willenbacher, W.; Eller, K.; Wolf, D.; Seifert, M.; Sun, C.C.; Babitt, J.L.; Hong, C.C.; Menhall, T.; Gearing, P.; Lin, H.Y.; Weiss, G. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood, 2011, 118(18), 4977-4984.
331. Fujiwara, T.; Ikeda, T.; Nagasaka, Y.; Okitsu, Y.; Katsuoka, Y.; Fukuhara, N.; Onishi, Y.; Ishizawa, K.; Ichinohasama, R.; Tomosugi, N.; Harigae, H. A low-molecular-weight compound K7174 represses hepcidin: possible therapeutic strategy against anemia of chronic disease. PLoS One, 2013, 8(9), e75568.
332. Patel, N.; Masaratana, P.; Diaz-Castro, J.; Latunde-Dada, G.O.; Qureshi, A.; Lockyer, P.; Jacob, M.; Arno, M.; Ma-tak, P.; Mitry, R.R.; Hughes, R.D.; Dhawan, A.; Patterson, C.; Simpson, R.J.; McKie, A.T. BMPER protein is a negative regulator of hepcidin and is up-regulated in hypotrans-ferrinemic mice. J. Biol. Chem., 2012, 287(6), 4099-4106.
333. Fatih, N.; Camberlein, E.; Island, M.L.; Corlu, A.; Ab-gueguen, E.; Détivaud, L.; Leroyer, P.; Brissot, P.; Loréal, O. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J. Mol. Med., 2010, 88(5), 477-486.
334. van Eijk, L.T.; John, A.S.; Schwoebel, F.; Summo, L.; Vauléon, S.; Zöllner, S.; Laarakkers, C.M.; Kox, M.; van der Hoeven, J.G.; Swinkels, D.W.; Riecke, K.; Pickkers, P. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood, 2014, 124(17), 2643-2646.
335. Ferrari, P.; Mallon, D.; Trinder, D.; Olynyk, J.K. Pentoxi-fylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton), 2010, 15(3), 344-349.
336. Johnson, D.W.; Pascoe, E.M.; Badve, S.V.; Dalziel, K.; Cass, A.; Clarke, P.; Ferrari, P.; McDonald, S.P.; Morrish, A.T.; Pedagogos, E.; Perkovic, V.; Reidlinger, D.; Scaria, A.; Walker, R.; Vergara, L.A.; Hawley, C.M. A randomized, placebo-controlled trial of pentoxifylline on erythro-poiesis-stimulating agent hyporesponsiveness in anemic pa-tients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. Am. J. Kidney Dis., 2015, 65(1), 49-57.
337. Zhang, L.; Coombes, J.; Pascoe, E.M.; Badve, S.V.; Dalziel, K.; Cass, A.; Clarke, P.; Ferrari, P.; McDonald, S.P.; Morrish, A.T.; Pedagogos, E.; Perkovic, V.; Reidlin-ger, D.; Scaria, A.; Walker, R.; Vergara, L.A.; Hawley, C.M.; Johnson, D.W. The effect of pentoxifylline on oxida-tive stress in chronic kidney disease patients with erythro-poiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep., 2016, 21(1), 14-23.
338. Isaacs, J.D.; Harari, O.; Kobold, U.; Lee, J.S.; Bernasconi, C. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res. Ther., 2013, 15(6), R204.
339. Casper, C.; Chaturvedi, S.; Munshi, N.; Wong, R.; Qi, M.; Schaffer, M.; Bandekar, R.; Hall, B.; van de Velde, H.; Vermeulen, J.; Reddy, M.; van Rhee, F. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuxi-mab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clin. Cancer Res., 2015, 21(19), 4294-4304.
340. Cooke, K.S.; Hinkle, B.; Salimi-Moosavi, H.; Foltz, I.; King, C.; Rathanaswami, P.; Winters, A.; Steavenson, S.; Begley, C.G.; Molineux, G.; Sasu, B.J. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood, 2013, 122(17), 3054-3061.
341. Song, S.N.; Iwahashi, M.; Tomosugi, N.; Uno, K.; Yamana, J.; Yamana, S.; Isobe, T.; Ito, H.; Kawabata, H.; Yoshizaki, K. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis pa-tients. Arthritis Res. Ther., 2013, 15(5), R141.
342. Kawabata, H.; Tomosugi, N.; Kanda, J.; Tanaka, Y.; Yoshi-zaki, K.; Uchiyama, T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castlemans disease. Haematologica, 2007, 92(6), 857-858.
343. Sun, C.C.; Vaja, V.; Chen, S.; Theurl, I.; Stepanek, A.; Brown, D.E.; Cappellini, M.D.; Weiss, G.; Hong, C.C.; Lin, H.Y.; Babitt, J.L. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol. Dial. Transplant., 2013, 28(7), 1733-1743.
344. Gummer, J.; Trengove, R.; Pascoe, E.M.; Badve, S.V.; Cass, A.; Clarke, P.; McDonald, S.P.; Morrish, A.T.; Peda-gogos, E.; Perkovic, V.; Reidlinger, D.; Scaria, A.; Walker, R.; Vergara, L.A.; Hawley, C.M.; Johnson, D.W.; Olynyk, J.K.; Ferrari, P. Association between serum hepcidin-25 and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: A secondary analysis of the HERO trial. Nephrology (Carlton), 2016, May 12. doi: 10.1111/nep.12815.
345. Antunes, S.A.; Vilela, R.Q.; Vaz, J.D.; Canziani, M.E. Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis. Int. J. Artif. Organs, 2014, 37(7), 521-528.
346. Farag, M.M.; Khalifa, A.A.; Elhadidy, W.F.; Rashad, R.M. Hepatorenal protection in renal ischemia/reperfusion by celecoxib and pentoxifylline. J. Surg. Res., 2016, 204(1), 183-191.
347. Besarab, A.; Chernyavskaya, E.; Motylev, I.; Shutov, E.; Kumbar, L.M.; Gurevich, K.; Chan, D.T.; Leong, R.; Poole, L.; Zhong, M.; Saikali, K.G.; Franco, M.; Hemmerich, S.; Yu, K.H.; Neff, T.B. Roxadustat (FG-4592): Correction of anemia in incident dialysis patients. J. Am. Soc. Nephrol., 2016, 27(4), 1225-1233.
348. Besarab, A.; Provenzano, R.; Hertel, J.; Zabaneh, R.; Klaus, S.J.; Lee, T.; Leong, R.; Hemmerich, S.; Yu, K.H.; Neff, T.B. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol. Dial. Transplant., 2015, 30(10), 1665-1673.
349. Brigandi, R.A.; Johnson, B.; Oei, C.; Westerman, M.; Ol-bina, G.; de Zoysa, J.; Roger, S.D.; Sahay, M.; Cross, N.; McMahon, L.; Guptha, V.; Smolyarchuk, E.A.; Singh, N.; Russ, S.F.; Kumar, S. PHI112844 Investigators. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: A 28-day, phase 2A randomized trial. Am. J. Kidney Dis., 2016, 67(6), 861-871.
350. Bernhardt, W.M.; Wiesener, M.S.; Scigalla, P.; Chou, J.; Schmieder, R.E.; Günzler, V.; Eckardt, K.U. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J. Am. Soc. Nephrol., 2010, 21(12), 2151-2156.
351. Flamme, I.; Oehme, F.; Ellinghaus, P.; Jeske, M.; Kelden-ich, J.; Thuss, U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 853934 (Molidustat) stimulates erythro-poietin production without hypertensive effects. PLoS One, 2014, 9(11), e111838.
352. Pergola, P.E.; Spinowitz, B.S.; Hartman, C.S.; Maroni, B.J.; Haase, V.H. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int., 2016, 90(5), 1115-1122.
353. Bartnicki, P.; Kowalczyk, M.; Rysz, J. The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection. Med. Sci. Monit., 2013, 19, 599-605.